Seattle Genetics Inc (SGEN)

SGEN (NASDAQ:Drugs)
$41.15
pos +0.33
+0.81%
Today's Range: 40.31 - 41.17 | SGEN Avg Daily Volume: 952,100
Last Update: 09/16/14 - 1:21 PM EDT
Volume: 501,822
YTD Performance: 2.33%
Open: $41.02
Previous Close: $40.82
52 Week Range: $32.35 - $55.99
Oustanding Shares: 123,447,871
Market Cap: 5,109,507,381
6-Month Chart
TheStreet Ratings Grade for SGEN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 3
Moderate Buy 0 0 0 0
Hold 3 3 2 4
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.56 2.56 2.50 2.78
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -68.98
Price Earnings Comparisons:
SGEN Sector Avg. S&P 500
-68.98 0.00 28.67
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
1.82% -15.80% 118.06%
GROWTH 12 Mo 3 Yr CAGR
Revenue 27.70 1.51 0.35
Net Income 0.00 -0.06 0.00
EPS 0.00 -0.23 0.00
Earnings for SGEN:
EBITDA -0.05B
Revenue 0.27B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $-0.25 $-0.29 $-0.82 $-0.63
Number of Analysts 8 7 9 9
High Estimate $-0.15 $-0.26 $-0.70 $-0.26
Low Estimate $-0.30 $-0.36 $-0.95 $-1.03
Prior Year $-0.19 $-0.13 $-0.51 $-0.82
Growth Rate (Year over Year) -32.24% -121.98% -59.91% 22.62%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Bob Byrne

 | Jun 11, 2014 | 7:30 AM EDT

A HERO may still emerge.

By

Jim Cramer

 | Jun 9, 2014 | 3:03 PM EDT

Become more aggressive about the real valuations of companies.

By

Bob Byrne

 | Jun 5, 2014 | 7:30 AM EDT

The $193 level on the SPY will be key today.

By

Bob Byrne

 | May 29, 2014 | 7:30 AM EDT

Thursday's SPY trade plan will involve fading the edges,

By

Jim Cramer

 | May 27, 2014 | 4:02 PM EDT

You're looking at one.

bullishSeattle Genetics upgraded at BofA/Merrill

May 6, 2014 | 7:19 AM EDT

SGEN was upgraded to Neutral, Bank of America/Merrill Lynch said. Valuation call, based on a $40 price target. 

By

Jim Cramer

 | Mar 29, 2014 | 8:00 AM EDT

TheStreet's Jim Cramer says newer pharmaceutical companies, like Celgene (CELG), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN), should be bought on any weakness because they have the potential to perform extremely well and may be better buys than Pfizer, Merck, Bristol-Myers and Eli Lilly.

By

Jim Cramer

 | Mar 23, 2014 | 6:00 AM EDT

For these kinds of growth stocks, you have no choice but to wait.

By

Jim Cramer

 | Mar 22, 2014 | 6:00 AM EDT

Here are some specific stocks working as parables right now.

By

Jim Cramer

 | Mar 19, 2014 | 8:04 AM EDT

It's sardonic, corroded commentary designed to keep your pole in the boat.

Per Brad Safalow at PAA Research, who knows this space better than most: Setting a precede...
Oil giant Exxon Mobil (XOM) was being dumped last Friday as fears of Russian sanctions wer...
WYNN has violated the first key support decision on the weekly chart, but is still holding...
The 10yr note, while lower in yield today (currently 2.56%), has seen a 16bp move higher o...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.